NanoViricides (NNVC) Competitors $1.50 +0.03 (+2.04%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$1.48 -0.02 (-1.33%) As of 08/15/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NNVC vs. ANEB, MGNX, ZURA, ANIX, IVVD, CHRS, VIRI, TCRX, IPA, and VTGNShould you be buying NanoViricides stock or one of its competitors? The main competitors of NanoViricides include Anebulo Pharmaceuticals (ANEB), MacroGenics (MGNX), Zura Bio (ZURA), Anixa Biosciences (ANIX), Invivyd (IVVD), Coherus Oncology (CHRS), Virios Therapeutics (VIRI), TScan Therapeutics (TCRX), ImmunoPrecise Antibodies (IPA), and VistaGen Therapeutics (VTGN). These companies are all part of the "pharmaceutical products" industry. NanoViricides vs. Its Competitors Anebulo Pharmaceuticals MacroGenics Zura Bio Anixa Biosciences Invivyd Coherus Oncology Virios Therapeutics TScan Therapeutics ImmunoPrecise Antibodies VistaGen Therapeutics NanoViricides (NYSE:NNVC) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations. Which has more risk & volatility, NNVC or ANEB? NanoViricides has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500. Comparatively, Anebulo Pharmaceuticals has a beta of -0.88, suggesting that its share price is 188% less volatile than the S&P 500. Does the media favor NNVC or ANEB? In the previous week, Anebulo Pharmaceuticals had 5 more articles in the media than NanoViricides. MarketBeat recorded 5 mentions for Anebulo Pharmaceuticals and 0 mentions for NanoViricides. Anebulo Pharmaceuticals' average media sentiment score of 0.76 beat NanoViricides' score of 0.00 indicating that Anebulo Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment NanoViricides Neutral Anebulo Pharmaceuticals Positive Do insiders and institutionals have more ownership in NNVC or ANEB? 10.3% of NanoViricides shares are held by institutional investors. Comparatively, 28.4% of Anebulo Pharmaceuticals shares are held by institutional investors. 4.6% of NanoViricides shares are held by company insiders. Comparatively, 80.6% of Anebulo Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is NNVC or ANEB more profitable? NanoViricides' return on equity of -87.90% beat Anebulo Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets NanoViricidesN/A -87.90% -78.69% Anebulo Pharmaceuticals N/A -90.11%-84.53% Do analysts rate NNVC or ANEB? Anebulo Pharmaceuticals has a consensus price target of $5.50, suggesting a potential upside of 120.00%. Given Anebulo Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Anebulo Pharmaceuticals is more favorable than NanoViricides.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NanoViricides 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Anebulo Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has preferable valuation & earnings, NNVC or ANEB? Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than NanoViricides, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNanoViricidesN/AN/A-$8.29M-$0.70-2.14Anebulo PharmaceuticalsN/AN/A-$8.20M-$0.26-9.62 SummaryAnebulo Pharmaceuticals beats NanoViricides on 9 of the 13 factors compared between the two stocks. Get NanoViricides News Delivered to You Automatically Sign up to receive the latest news and ratings for NNVC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NNVC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NNVC vs. The Competition Export to ExcelMetricNanoViricidesPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$24.11M$778.25M$5.73B$20.96BDividend YieldN/A4.84%3.90%3.59%P/E Ratio-2.081.1622.3125.67Price / SalesN/A25.64444.1659.85Price / CashN/A19.5625.2217.81Price / Book2.276.599.254.56Net Income-$8.29M-$4.67M$3.26B$993.62M7 Day Performance-5.06%3.22%7.39%1.80%1 Month Performance-8.54%3.30%4.22%0.81%1 Year Performance-30.88%15.26%30.30%13.44% NanoViricides Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NNVCNanoViricides0.3099 of 5 stars$1.50+2.0%N/A-30.4%$24.11MN/A-2.0820ANEBAnebulo Pharmaceuticals2.2416 of 5 stars$2.37-1.7%$5.50+132.1%+26.3%$98.90MN/A-9.124News CoverageShort Interest ↑Gap UpMGNXMacroGenics4.3116 of 5 stars$1.47-4.5%$5.40+267.3%-51.1%$97.16M$149.96M-1.65430Trending NewsEarnings ReportUpcoming EarningsAnalyst ForecastZURAZura Bio3.6538 of 5 stars$1.41-0.7%$14.33+916.5%-49.4%$97.09MN/A-2.013News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionGap UpANIXAnixa Biosciences2.5914 of 5 stars$2.94-1.3%$9.00+206.1%-4.5%$95.99M$210K-7.745IVVDInvivyd3.6862 of 5 stars$0.77-3.5%$5.85+659.9%-27.6%$95.72M$25.38M-0.64100News CoverageEarnings ReportAnalyst ForecastShort Interest ↓Gap DownCHRSCoherus Oncology4.1902 of 5 stars$0.88+7.2%$4.68+432.0%-16.7%$95.17M$266.96M0.57330VIRIVirios TherapeuticsN/A$4.890.0%$5.00+2.2%+2,508.5%$94.17MN/A-18.115Gap DownTCRXTScan Therapeutics3.6707 of 5 stars$1.61-1.8%$7.80+384.5%-68.6%$92.81M$2.82M-1.48100Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionIPAImmunoPrecise Antibodies2.2795 of 5 stars$1.90-5.0%$4.00+110.5%+96.1%$92.31M$17.59M-2.7980Short Interest ↑Gap UpVTGNVistaGen Therapeutics1.085 of 5 stars$2.84-4.4%N/A+0.9%$91.12M$490K-1.6040News CoverageAnalyst Upgrade Related Companies and Tools Related Companies Anebulo Pharmaceuticals Alternatives MacroGenics Alternatives Zura Bio Alternatives Anixa Biosciences Alternatives Invivyd Alternatives Coherus Oncology Alternatives Virios Therapeutics Alternatives TScan Therapeutics Alternatives ImmunoPrecise Antibodies Alternatives VistaGen Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:NNVC) was last updated on 8/17/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredNew Federal Land Rush About to Start?A $100 Trillion Wealth Shift Is Already Underway Lithium. Oil. Gold. Trillions in U.S. resources are being ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NanoViricides, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NanoViricides With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access